Autifony Therapeutics

Autifony Therapeutics is a clinical-stage biotechnology company founded in 2011 as a spinout from GSK.

Based in Stevenage, UK, the company focuses on developing innovative medicines for rare and serious central nervous system (CNS) disorders by targeting the Kv3 family of ion channels. Their research aims to change treatment paradigms for conditions such as Fragile X syndrome, rare epilepsy, schizophrenia, and hearing disorders. The company operates a specialized ion channel drug discovery platform that develops small-molecule modulators to regulate neuronal excitability. Autifony's pipeline includes clinical-stage assets like AUT00206, which targets Fragile X syndrome and has received FDA Orphan Drug Designation, and AUT00063, aimed at tinnitus and age-related hearing loss. Additionally, they have preclinical programs addressing schizophrenia, Alzheimer’s disease, and rare epilepsy syndromes. Autifony collaborates with key investors and partners, including Boehringer Ingelheim and GSK, to advance their therapeutic approaches in the healthcare and biopharmaceutical market.